Introduction
Heart failure is a common, lethal, disabling, and expensive disorder. Its prevalence in industrialised nations has reached epidemic levels (ie, about 1 million cases in the UK 1 and nearly 6 million in the USA 2 ), and continues to rise. Despite advances over the past 30 years, the prognosis for patients who are admitted to hospital with heart failure remains poor, with a 5-year mortality that is nearly 50% 2 -worse than that for patients with breast or colon cancer. 3 The most common cause of heart failure in the west is ischaemic heart disease. 2 Available treatments do not address the fundamental problem of the loss of cardiac tissue. As a result, interest in attempts to repair the failing heart with the use of stem cells has been increasing, since this approach has the potential to regenerate dead myocardium and thus alleviate the underlying cause of heart failure. 4 The adult heart contains cardiac stem cells (CSCs) that express the surface receptor tyrosine kinase c-kit. [5] [6] [7] These cells are self-renewing, clonogenic, and multi potentie, they diff erentiate into all three major cardiac lineages (myocytes, vascular smooth muscle cells, and endothelial cells). 5, [7] [8] [9] [10] [11] Results of many studies have shown that transplantation of CSCs in animal models of post-myocardial-infarction heart failure attenuates left ventricular (LV) remodelling and improves LV function in the settings of acute and chronic myocardial infarctions. 5, [7] [8] [9] [10] [11] [12] Despite these encouraging preclinical results, however, the eff ects of CSCs in patients have not been investigated. We therefore undertook a phase 1 clinical trial of CSCs in patients with heart failure after myocardial infarction to assess the safety and feasibility of intracoronary CSC infusion and to test the hypothesis that this intervention would improve the contractile function of the heart and the general clinical status. Here we report the initial results.
Methods

Patients
The protocol is provided in the webappendix p 14. Stem Cell Infusion in Patients with Ischemic cardiOmyopathy (SCIPIO) was a phase 1, randomised, open-label, singlecentre trial of the administration of autologous CSCs in patients with severe heart failure secondary to ischaemic cardio myopathy. The target population were patients who underwent coronary artery bypass grafting (CABG), and had LV ejection fraction (EF) of less or equal to 40% and a previous myocardial infarction. Enrolment was based on eligibility screening at two timepoints. Initial screening took place within 2 weeks of CABG (fi gure 1). Inclusion criteria included age younger than 75 years, LVEF less or equal to 40%, and evidence of a myocardial scar. Other inclusion and exclusion criteria are provided in the webappendix p 5. Final screening was done 3-4 months after CABG by use of the same criteria. All variables of cardiac performance obtained at fi nal screening were regarded as baseline data.
The study protocol was reviewed and approved by the institutional review board for the University of Louisville, Louisville, KY, USA. An independent data and safety monitoring board reviewed the trial progress. Patients meeting initial eligibility criteria were approached within 2 weeks of CABG. Before enrolment, all patients agreed to participate and signed a statement of informed consent approved by the institutional review board. The study was done in accordance with the principles of the Declaration of Helsinki. Trial investi gators maintained compliance with the US Food and Drug Administration 
Randomisation and masking
SCIPIO was undertaken in two sequential stages (A and B). To assess the feasibility and short-term safety (ie, adverse eff ects) of CSCs, in stage A, nine consecutive patients were assigned to the treatment group followed by four consecutive patients to the control group (fi gure 1). In stage B, randomisation was done by two investigators (ARC and JHL) before the fi nal eligibility screening. Numbers assigned to patients were entered into a computer software program that randomly allocated treatment assignment in a 2:3 ratio by use of an adaptive block randomisation scheme and a block size of fi ve (fi gure 1). ARC and JHL assigned the patients. The purpose of adaptive block randomisation was to try to correct the imbalance between the control and the treated groups, resulting from most eligible patients wanting to be treated with CSCs. An open-label study design was used because masking would have required a cardiac catheterisation with placebo infusion in the control group. However, the investigator (MFS) doing the echocardiographic analyses was masked to group assignment.
Study design
At the time of CABG, the right atrial appendage was harvested at the Jewish Hospital, Louisville, KY, USA, and University of Louisville and shipped to the Brigham and Women's Hospital, Boston, MA, USA, where CSCs were isolated and expanded as described below. The nearly fi nal CSC product was transported to a Good Manufacturing Practice laboratory in Louisville for sterility testing, cell count, and assessment of viability. After confi rmation of negative microbial testing, the fi nal CSC product was prepared in 12 mL PlasmaLyte A (Baxter Healthcare, Deerfi eld, IL, USA) for infusion at the Jewish Hospital.
In patients assigned to the treatment group, autologous CSCs were administered by intracoronary infusion at a mean of 113 days (SE 4) after CABG. An over-the-wire balloon catheter (Quantum Maverick non-compliant balloon, Boston Scientifi c, Natick, MA, USA, or Voyager RX balloon, Abbott Laboratories, Abbott Park, IL, USA) was advanced into the proximal coronary artery or graft supplying the infarcted LV region. The balloon was infl ated for 3 min by use of low pressure to stop coronary fl ow during which time CSCs were infused distally through the central port of the catheter. Four infl ations with 3 min of intervening refl ow were done. The number of CSCs infused depended on the number and location of the infarcts. In patients with one myocardial scar, 1 million cells were infused into anterior wall infarcts and 500 000 cells into infarcts within the left circumfl ex or right coronary artery territories. In patients with several regions of infarction, 500 000 cells were infused into two diff erent vascular territories so as not to exceed a total of 1 million cells. After infusion of CSCs, patients were monitored during an overnight stay in hospital. Patients in the control group did not undergo cardiac catheterisation.
In treated patients, two-dimensional (2D) and threedimensional (3D) transthoracic echocardiograms, routine laboratory tests, physical examination, and New York Heart Association (NYHA) 13 class assessment were done before CSC infusion and at 1 month, 4 months, and 12 months thereafter. Additionally, routine laboratory tests and phys ical examination were done at 24 h, 1 week, 2 weeks, and 8 months after infusion of CSCs. The Minnesota Living with Heart Failure Questionnaire (MLHFQ) was completed by patients before CSC infusion and after 4 months and 12 months. In patients without contra indications, cardiac MRI (cMRI) was done before infusion of CSCs and 4 months and 12 months thereafter. A 24 h ambulatory monitor was used for detection of arrhythmias at 1 week and 4 weeks after CSC infusion.
Isolation and expansion of CSCs
The atrial samples were cut into small pieces (<1 mm³) and suspended in 2-5 mL Ham's F12 medium (Cambrex, East Rutherford, NJ, USA) containing 1-3 mg/mL collagenase NB 6 (Crescent Chemicals, Islandia, NY, USA). After digestion, cells were plated in petri dishes containing Ham's F12 medium supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT, USA), 100 ng/mL recombinant human basic fi broblast growth factor (PeproTech, Rocky Hill, NJ, USA), 0·2 mmol/L L-glutathione (SigmaAldrich, St Louis, MO, USA), and 5 mU/mL human erythropoietin (Sigma-Aldrich). Subsequently, cells were expanded and subjected to immunomagnetic sorting with microbeads (human CD117 MicroBead kit, Miltenyi Biotech, Auburn, CA, USA) to obtain c-kitpositive CSCs.
7,14 About 2 million CSCs were obtained per patient.
Characterisation of CSCs
To measure the fraction of c-kit-positive, lineage-negative cells in the preparation, a small sample of CSCs was fi xed in 4% paraformaldehyde and incubated for 45 min at 37°C with a c-kit antibody or a cocktail of primary antibodies recognising myocytes (GATA4, Nkx2. Ann Arbor, MI, USA) instruments. 5, 7, 14 Quantitative measure ments of telomere length were made by use of quantitative fl uorescence in situ hybridisation and confocal microscopy or fl ow fl uorescent in-situ hybridisation (fl ow-FISH). 7, 14, 15 The catalytic activity of telomerase was assessed by use of quantitative PCR. 14, 15 To measure population doubling time, CSCs were plated at low density (about 700/cm 2 ) and the number of cells was counted daily. Population doubling time was computed by use of linear regression of log 2 values of cell numbers. To assess the fraction of cells that were in senescence and irreversible growth arrest, cultures were stained for the senescenceassociated protein p16 INK ⁴ a . 7, 14, 15 More details about these methods are provided in the webappendix p 1.
Echocardiography
Full-volume real-time 3D echocardi ography images were obtained from an apical window. The entire LV was included for volumetric measurement by full-volume 3D datasets acquired by combining four electrocardiogram (ECG)-gated pyramidal subvolumes. Images were acquired over four cardiac cycles with a matrix array ultrasono graphic transducer (X3-1, Philips Medical Systems, Bothell, WA, USA). Measurements of 3D volumes and EF were done offl ine with a semiautomated algorithm by QLAB (version 3.1, Philips Medical Systems). From an apical full-volume acquisition, frames for LV end-diastolic volume and LV end-systolic volume measurement were identifi ed. Endocardial contour tracing was undertaken with a semiautomatic border detection algorithm and manually adjusted if needed: after identifi cation of the apex and mitral annulus on four-chamber and two-chamber slices, a preconfi gured ellipse was automatically fi tted to the endocardial borders of each frame and manually adjusted as required in appropriate planes. LV end-diastolic volume and LV endsystolic volume were measured from the 3D volumes, and the EF was derived. All measure ments were done by an experienced echocardiographer (MFS). Wall motion analysis was done by use of the 16-segment model from standard parasternal and apical 2D echocardiographic views as recommended by the American Society for Echocardiography. 16 cMRI cMR images were acquired by use of a 1.5T Espree system (Siemens Medical Solutions, Erlangen, Germany). Cardiac-gated, TrueFISP Cine (Siemens Medical Solutions) acquisitions (25 temporal frames) were done during breath holding, with phased array reception coils. Typical parameters were repetition time 5 ms, echo time 1·5 ms, fl ip angle 80° with a spatial resolution of 1·4 mm × 3·1 mm in plane. Default slice thickness was 8 mm, with ten to 12 short-axis image sections for complete coverage of the left ventricle. Late gadolinium enhancement for infarct assessment was also done with Multihance (Bracco, Milan, Italy) at 0·2 mmol/L per kg. Typical acquisition entailed a phase-sensitive inversion recovery technique with a spatial resolution 2·1 × 2·1 × 8·0 mm³. Post-processing was done with QMass software (version 7.2). Assessment of infarct size was done both semi quantitatively (with a standard transmural categorisation score 17 of 1-4, with 1 representing no infarct, 2 less than 25% transmural involvement, 3 25-50%, 4 more than 50%) and quantitatively with manual delineation in a slice-by-slice analysis with infarct tissue expressed in g. 18 
Statistical analysis
The primary endpoint was the safety and feasibility of autologous CSCs for the treatment of heart failure resulting from ischaemic heart disease. The secondary endpoint was 
Role of the funding source
The sponsors of the study had no role in study design, data collection, analysis, and interpretation, or writing the report. The corresponding author had full access to all the data and had fi nal responsibility for the decision to submit the report for publication. Figure 1 summarises the numbers of patients screened, enrolled, and excluded. The study is still in progress; here we report the interim results obtained in 16 CSCtreated and seven control patients. Table 1 summarises the characteristics of the patients in the CSC-treated and control groups. There were no signifi cant diff erences between groups at the time of CABG except for tobacco use, which was more prevalent in the control group. Analysis at the time of fi nal enrolment (about 4 months after CABG) showed no signifi cant diff erences between groups, including the use of tobacco. By design, all patients had at least one previous myocardial infarction; the mean age of the infarct was 3·7 years (SE 0·9). Five of seven control and 15 of 16 CSC-treated patients had evidence of a transmural myocardial infarction (details provided in webappen dix p 2). 15 patients were administered 1 million CSCs and one was administered 500 000 CSCs; in this patient, LVEF increased by 16·7 units at 4 months after administration of CSCs.
c-kit-positive CSCs were characterised by use of immunolabelling, confocal microscopy, and FACS analysis (fi gure 2A; webappendix pp 9,11). The fraction of c-kit-positive cells varied from 75·0% to 98·0% (mean 88·0% [SE 1·7]; fi gure 2B). CSCs committed to the myocyte, smooth muscle cell, and endothelial cell lineages constituted 0·1-2·7% of the population (1·1% [0·2] ; fi gure 2B). Mean telomere length was 7·5 kbp (range 6·8-8·1; fi gure 3B; webappendix p 10), and was much higher than the lengths associated with senescence of human cells-ie, 1·5-2·0 kbp. 19 Additionally, telomerase activity was high in all CSC samples (fi gure 3C). The signifi cant growth reserve of CSCs was confi rmed by use of the population doubling time, which was never greater than 31 h (fi gure 3D). The well preserved telomere-telomerase axis in CSCs was consistent with the quite small percentage of CSCs that were positive for the senescence-associated protein p16 INK ⁴ a (fi gure 2C; webappendix p 12), which permanently prevents the reentry of stem cells into the cell cycle. 20 Thus, CSCs expanded in culture retained a robust capacity for further cell division. There was no relation between age of the patients and either telomere length or telomerase activity (data not shown).
Two CSC-treated patients could not be included in the echocardiographic analysis because of poor image quality (n=1) and uncorrected aortic stenosis (n=1). In the remaining 14 treated patients, LVEF, assessed by use of 3D echocardiography, increased progressively from a mean of 30·3% (SE 1·9) before CSC infusion to 35·9% (2·7) 1 month after infusion of CSCs (p=0·014) and 38·5% (2·8) 4 months after infusion (p=0·001; fi gure 4A). In the eight patients who completed the 1 year of followup, LVEF increased further from 39·2% (3·6) at 4 months to 42·5% (4·1) at 1 year (fi gure 4B); although the increase from 4 months to 12 months was not signifi cant (p=0·159), it suggests that CSCs continue to improve LV function beyond the fi rst 4 months. The absolute increase in LVEF from baseline was 8·2 EF units (2·0) at 4 months in 14 patients and 12·3 EF units (2·1) at 12 months in eight patients (fi gure 4C). An improvement in LVEF was noted in 12 of 14 patients at 4 months (fi gure 4A) and in all eight patients who completed follow-up at 1 year (fi gure 4B). By contrast, in the seven control patients with 4 months of follow-up, none of these values changed much over the same time interval-eg, mean LVEF was 30·1% (2·4) at baseline (4 months after CABG) and 30·2% (2·5) at 4 months after baseline (fi gure 4A).
The increase in LVEF in the 14 CSC-treated patients was associated with an improvement in the regional wall motion score index, both in the infused LV regions cMRI with gadolinium was undertaken in seven CSCtreated patients. Reasons for exclusion were placement of implan table cardioverter defi brillator, estimated glomerular fi ltration rate of less than 40 mL/min per 1·73 m², and non-CABG postoperative status with recently placed metal hardware. The mean infarct weight, assessed with cMRI, was 32·6 g [SE 6·3] before infusion of CSCs, and decreased by 7·8 g (1·7; 24%) at 4 months after treatment and 9·8 g (3·5; 30%) at 12 months (fi gure 5). A reduction in infarct size was also noted with the semiquantitative infarct score index (webappendix p 13). Measurements of LV wall thickening with cMRI showed a signifi cant (p=0·01) improvement at 4 months (webappendix p 13), confi rming the echocardiographic data.
In the 16 CSC-treated patients, the NYHA functional class decreased from a mean of 2·19 (SE 0·16) before CSC infusion to 1·63 (0·16) 4 months after infusion (fi gure 6A). Quality of life, as assessed by use of the mean MLHFQ score, improved substantially from 46·44 (5·22) to 26·69 (4·92; fi gure 6C). In the seven control patients, neither the NYHA class nor the MLHFQ score changed much over the corresponding 4 months (NYHA 2·0 No adverse eff ects attributable to CSCs were noted (table 2) . Specifi cally, none of the CSC-treated patients had non-fatal myocardial infarction (immediately after CSC infusion or during follow-up), death, tumour formation, ventricular arrhythmias, systemic infection, stroke, allergic reactions, or coronary revascularisation. With 24 h ambulatory ECG monitoring on two separate occasions (1 week and 4 weeks after CSC treatment), no tachyarrhythmias were noted. One treated patient was admitted to hospital for heart failure, one treated patient and two control patients were admitted for angina, and one control patient underwent percutaneous coronary revascularisation. In one treated patient, a dissection of the left internal mammary artery graft occurred during balloon infl ation; the dissection was repaired with a stent and no complications arose over the following 2 years. Information from the SCIPIO trial about the safety and feasibility of administration of CSCs to patients is further described in webappendix p 2.
Discussion
Our results suggest that CSCs can be reproducibly isolated and expanded from about 1 g myocardial tissue that is harvested during cardiac surgery. Infusion of 1 million autologous CSCs is not associated with apparent adverse eff ects for up to 1 year; and infusion of autologous CSCs results in a substantial improvement in LV systolic function 4 months after infusion and an even more pronounced improvement 1 year after infusion and is associated with increased functional capacity, improved quality of life, and reduced LV scar size.
CSCs are particularly attractive for cardiovascular applications because they normally reside in the adult heart and can be reproducibly isolated and expanded, even from endomyocardial biopsies.
14 These cells are thought to replenish the pool of cardiac myocytes and cardiac vascular cells that die during an organism's lifetime. [5] [6] [7] [8] The initial results of SCIPIO are consistent with the salutary eff ects of CSCs reported in preclinical studies 5, [7] [8] [9] [10] [11] and compare favourably with the results of previous clinical studies of a variety of non-cardiac stem or progenitor cells in patients with ischaemic cardiomyopathy (webappendix p 6). 4 In particular, the increase in LVEF in this study compares very favourably with the 3-7% improvement reported in previous studies of intracoronary infusion of bone marrow mononuclear cells in similar patient populations (panel). [21] [22] [23] [24] The optimum dose of CSCs remains to be established. The dose of CSCs used in SCIPIO (1 million) was selected conservatively on the basis of preclinical studies in pigs 8 and the growth characteristics of the cells. Our CSC population had a mean telomere length of 7·5 kbp (fi gure 3B). Because 130 bp of telomeric DNA are lost after each division 7 and senescence occurs when telomeres reach 1·5-2·0 kbp, a single engrafted CSC could, in principle, divide 42 times before irreversible growth arrest, generating 4×10¹² cells. We have shown that CSCs can be isolated and expanded from small (about 5 mg) endomyocardial biopsies.
14 In future studies, assessment of the eff ects of larger numbers of autologous CSCs will be possible and in a much wider population of patients with heart failure by use of endomyocardial biopsies. Since CSCs can be frozen for subsequent use, even better results might be obtained with repeated infusions in the same patient.
We elected to deliver CSCs at a mean of almost 4 months after CABG to allow resolution of myocardial stunning or hibernation, 28 and any improvement to occur in LV function secondary to revascularisation. The high number of patients who were excluded because of an increase in LVEF during the fi rst 4 months after CABG lends support to the appropriateness of this decision (fi gure 1). The general agreement is that, by 4 months after CABG, stunned or hibernating myocardium has recovered and LV function is fairly stable. [29] [30] [31] Indeed, no improvement was noted in the seven control patients. Therefore, the improvement in LV systolic performance noted in CSC-treated patients was unlikely to be indicative of the eff ects of CABG.
The reduction in infarct size noted by use of cMRI is consistent with cardiac regeneration, although whether regeneration, if it occurred, was mediated by diff erentiation of the injected CSCs, activation of resident CSCs, or both is not known. Answering this crucial question will necessitate the development of strategies to track the long-term fate of CSCs in patients. Other mechanisms (eg, paracrine actions resulting in inhibition of apoptosis, inhibition of fi brosis, or enhanced contractile performance) cannot be excluded. Irrespective of the mechanism, it is noteworthy that autologous CSCs improved LV performance despite the presence of mature scars. Hospital admission for heart failure † 1 (6%) 0
Hospital admission for angina 1 (6%) 2 (29%)
NA=not applicable. *Tortuous left internal mammary artery engaged for cardiac-stem-cell infusion had intimal dissection after balloon defl ation; drug-eluting stent was placed without complication. †Secondary to worsening valvular disease. Limitations of SCIPIO include the small number of patients and the absence of placebo-treated patients (which resulted in the open-label design). These features, which are common to many phase 1 trials, result from the novel nature of the treatment, and from the fact that masking was not possible because it would have necessitated intracoronary infusion of vehicle; never theless, all echocardiograms were analysed without knowledge of treatment allocation. Any potential conditioning eff ect of the brief coronary occlusions in treated patients would be short lived (48-72 h), 28 and thus could not account for the long-term benefi ts. We emphasise that SCIPIO was designed to investigate the safety and feasibility of intracoronary CSC infusion in patients with severe heart failure, not to assess effi cacy. All effi cacy data need to be verifi ed in larger studies.
In conclusion, the initial results of SCIPIO suggest that intracoronary infusion of autologous CSCs in patients with chronic ischaemic cardiomyopathy and severe heart failure is feasible, safe, and apparently highly effi cacious in restoring LV systolic function up to 1 year after treatment. Since SCIPIO is the fi rst study of CSCs in human beings, the results will be important for developing this new form of cell therapy. The data from our study warrant further, larger, phase 2 studies.
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